#85 Research Authority
Peer-reviewed research curated for clinical relevance and evidence quality.
Recent research digest. 5 of 5 most recent studies from our monitored feeds.
Characterization of Women’s Health Benefit Claims Made on Cannabis E-Commerce Platforms: A Retrospective Market Surveillance Study.
Nali Matthew C et al.
American journal of preventive medicine • 2026
# Clinical Summary This study analyzed cannabis product claims on major e-commerce platforms and found that many products marketed health benefits related to women’s reproductive health and wellness despite limited scientific evidence supporting these claims. The findings highlight potential consumer risks from unregulated marketing of cannabis products to women seeking reproductive health solutions.
Endocannabinoid modulation of a reciprocal fronto-coerulear connection in contextual discrimination.
Locarno Andrea et al.
Cell reports • 2026
# Clinical Summary This study reveals that the brain’s prefrontal cortex communicates with the locus coeruleus through a two-way circuit that uses endocannabinoids to regulate norepinephrine release and control attention and decision-making. The findings suggest that endocannabinoid signaling acts as a brake on this circuit, helping the brain fine-tune arousal and cognitive control during tasks requiring contextual discrimination.
Topical application of cannabidiol for muscle recovery after exercise-induced muscle damage: a randomized, double-blinded pilot study.
Mendes Antoine et al.
Journal of cannabis research • 2026
Cannabis consumption and problematic internet use: analysis of a free-text response collected through a self-reported online questionnaire.
St-Onge Juliette et al.
BMC psychology • 2026
Towards an Optimal Decision Threshold for Specific IgE to rCan s 3 the Non-Specific Lipid Transfer Protein of Cannabis sativa.
Ebo Didier G et al.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology • 2026
# Clinical Summary Researchers developed a fluorescence enzyme immunoassay test to measure allergic antibodies (specific IgE) against Can s 3, a major allergen in cannabis, in order to establish an optimal diagnostic cutoff value for identifying cannabis allergic patients. The study compared this new test method with existing diagnostic techniques in 104 cannabis-allergic patients, 20 healthy controls, and 70 exposed non-allergic controls to determine which threshold level
Digest generated March 25, 2026 at 11:34 AM